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Abstract
Background: Tumor necrosis factor antagonist inhibitors have transformed the approach to patients with severe
autoimmune conditions, such as rheumatoid arthritis. Although the therapy can be highly effective, TNF-α inhibitors
are associated with an increased risk of opportunistic infections.
Case presentation: Here, we report a case of concomitant disseminated histoplasmosis and tuberculosis in a
65-year-old female with rheumatoid arthritis treated with TNF-α inhibitor. Both conditions can be found in
disseminated form in immunosuppressed hosts, but co-infection is rare with only a few cases having been
reported, to our knowledge, all in HIV patients.
Conclusions: This case posed a considerable challenge for diagnosis and treatment due to the unusual
disseminated co-infection, the overlapping symptoms, and the interactions between medications.
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Background
Histoplasmosis is a systemic fungal disease acquired by
inhalation of microconidia from the fungus Histoplasma
capsulatum. Distribution is worldwide where it can be
found in soil and in the droppings of birds and bats [1].
The spores are initially inhaled, reaching the alveoli, where
they transform into budding yeast cells. Subsequently, the
macrophages phagocytize the yeast although sometimes
they are unable to eliminate it, which allows the yeast to
multiply and spread via the lymphatic system. Once cell-
mediated immunity develops, the new macrophages may
eliminate the yeast or create a wall of histoplasma around
it forming granulomas [1]. Tuberculosis (TB) is a global
disease caused by Mycobacterium tuberculosis. It spreads
from human to human via inhaled infectious particles
through the lungs, and its resurgence has been associ-
ated with the human immunodeficiency virus (HIV)
epidemic [2]. In 2014, the World Health Organization
estimated that 9.6 million people had contracted TB
and 1.5 million died. About 12% of the 9.6 million new
TB cases were HIV-positive with 400 thousand deaths
in the HIV-positive population [2]. In general, once the
infected droplets are inhaled, the infection progresses
in a similar fashion to histoplasmosis. Initially, the bacilli
may multiply both in the alveoli and inside the macro-
phage until cell-mediated immunity develops. The infec-
tion can be controlled with the formation of a granuloma,
where the CD4+ cells and Tumor necrosis factor alpha
(TNF-α) macrophages are key factors for reactivation sur-
veillance. However, new epidemiological and genetic data
support the fact that in some instances, the body can suc-
cessfully eradicate M. tuberculosis infection before an
adaptive immune response develops, which is referred as
early clearance [3]. It is important to point out that both
Histoplasmosis and TB can be found in disseminated
form in immunosuppressed hosts, yet co-infection is rare
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with only a few cases having been reported, to our know-
ledge all in HIV patients [4]. We are reporting a case of an
immunosuppressed patient due to TNF-α inhibitor ther-
apy, who was co-infected with Hisptolasmosis and TB,
both in disseminated form.
Case presentation
A 65-year-old female with rheumatoid arthritis treated
with a TNF-α inhibitor (Adalimumab) presented to her
primary care physician with episodes of malaise, dyspnea,
fever, weight loss and pleural effusions on and off for six
months. She underwent medical evaluation at another
institution without obtaining a clear diagnosis. Since
Adalimumab has also been associated with lymphoma and
other cancers, the patient underwent an abdominal
computerized tomography (CT) that revealed multiple
hypoattenuating lesions in the spleen and retroperiton-
eal lymphadenopathy in the periportal, peripancreatic
and mesenteric regions, some with necrotic appear-
ance (Fig. 1a). A needle biopsy was done on the spleen,
which showed multiple caseating granulomas and the
use of special stains revealed the absence of acid fast
bacilli but identified thin-walled yeast-like organisms
with distinctive histopathological characteristics con-
sistent with histoplasmosis. The patient was then
referred to our institution and hospitalized due to dis-
seminated Histoplasmosis.
At presentation the patient looked chronically ill, but
was afebrile with stable vital signs. The physical examin-
ation was unremarkable except for her advanced interpha-
langeal joint deformities. Additional laboratory studies
showed the white blood cell (WBC) count was 8,100/μL
with a neutrophil count of 80.9%, the C-reactive protein
level (CRP) was 10.20 mg/dL and ferritin was 1,827.34 ng/
mL. The blood chemistry data revealed low protein levels
(5.2 g/dL), low albumin levels (2.5 g/dL), no electrolyte
imbalance and preserved renal and hepatic functions. An
HIV test and Histoplasma serology came back negative. A
Chest X-ray was negative.
During detailed history the patient reported a hobby of
caring for pigeons. Further history revealed she had
positive tuberculosis skin tests (TST) on multiple occa-
sions, in addition to caring for a family member with
tuberculosis. Despite this, the patient had never received
treatment for latent tuberculosis as she had normal chest
x-rays. Treatment for disseminated histoplasmosis was
started with amphotericin B lipid formulation while fur-
ther evaluation for tuberculosis was initiated. Reevalua-
tion for tuberculosis revealed a positive TST at 30 mm.
Additional lung evaluation was done with a CT scan
which showed extensive bilateral centrilobular nodules
with areas of cavitation in the upper lung lobes in a mil-
iary pattern (Fig. 1b). The CT also revealed additional
findings such as prevascular lymphadenopathy and par-
enchymal lesions. The patient’s sputum smear was evalu-
ated due to concern of further Histoplasma spreading. It
was negative for fungus by KOH/Calcofluor test yet was
positive for acid fast bacilli (AFB). The culture identified
by DNA probe was positive for M. tuberculosis complex,
and subsequently positive for M. tuberculosis by specific
Polymerase Chain Reaction (PCR). The bronchoalveolar
lavage (BAL) smear and culture were also negative for
fungus and positive for AFB and identified by DNA
probe and PCR as M. tuberculosis. This allowed us to
rule out Histoplasmosis as the cause of the miliary pattern
observed on her CT, and to move towards a diagnosis of
concomitant disseminated histoplasmosis and tuberculosis.
A four-drug regimen of isoniazid, rifampin, etham-
butol and pyrazinamide for tuberculosis was started
which was well tolerated. The patient did not tolerate
the full cycle of amphotericin B, so transition to itraco-
nazole was started before the 2 week induction regimen
could be completed. Given a severe interaction between
rifampin and itraconazole, rifampin was later replaced
with levofloxacin. Though initially well tolerated, our
Fig. 1 a Axial CT abdomen image demonstrates numerous hypo-attenuating lesions on spleen, almost replacing the normal parenchyma. b Axial
CT chest image reveling reticulonodular infiltrates with tree in bud and cavitations
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patient developed a clinical respiratory deterioration
that required mechanical ventilation. We suspected Im-
mune Reconstitution Inflammatory Syndrome (IRIS), thus
methylprednisolone was added to the treatment. However,
after 72 h of treatment the medication was withdrawn due
to upper gastrointestinal bleeding. The tuberculosis treat-
ment was not withdrawn or altered further. After a week
of supportive treatment the patient improved clinically
and was extubated. After 35 days of intra-hospital care,
the sputum samples cleared and the patient was dis-
charged to continue outpatient treatment at the Puerto
Rico Health Department Tuberculosis Clinics.
Discussion
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
have transformed the therapeutic approach to patients
with severe autoimmune conditions, such as rheumatoid
arthritis, psoriasis and inflammatory bowel disease. These
therapies, including TNF-α inhibitors, although highly ef-
fective, can produce profound immune suppression and
predispose patients to common upper respiratory tract in-
fections as well as reactivation of cell mediated controlled
infections [5]. Both histoplasma and tuberculosis have
been increasingly reported with the use of TNF-α inhibi-
tor. Consequently the Food and Drug Administration
(FDA) has issued a “black box” warning in an attempt to
increase awareness of this problem [5]. The Center for
Disease Control and Prevention (CDC) recommends TB
testing before initiating immunosuppressive therapy [6].
TST and Interferon-Gamma Release Assays (IGRAs) can
be used to screen for latent TB and data suggests that
IGRAs are not inferior to TST [6, 7]. An initial chest x-ray
is also recommended for baseline measurement. These
images may aid in identifying occult active infections like
cavitations, which would require multi-drug therapy [6].
This case shows the importance of adhering to the
current recommendations in which positive TST re-
quires pharmacotherapy independently of the findings
on the chest X-ray. This is especially important when
patients are being evaluated for therapies that suppress
cell immunity, since reactivation of latent TB is signifi-
cantly higher in patients receiving TNF-α inhibitors.
Previous studies have shown a five-fold increased risk
of reactivation within the first 52 weeks after initiation
of therapy [8].
In contrast, currently there are no definitive recommen-
dations for histoplasmosis screening [9]. There was a His-
toplasma skin test analog to TST but it is no longer
commercially available due to cross-reactions with other
fungi and low sensitivity in patients with disseminated in-
fection [1]. Furthermore, no therapy recommendations
have been studied to prevent histoplasmosis reactivation.
This gap in knowledge is important, as the disease can
disseminate to bone marrow, liver, spleen, adrenal glands,
and meninges with a mortality rate of up to 20% [4].
The disseminated form of histoplasmosis is defined by
the presence of an extra-pulmonary focus. In some in-
stances, patients show obvious widespread dissemin-
ation but in others, focal disease in a single organ is the
only manifestation of dissemination [9]. In our patient,
the histoplasmosis dissemination was manifested by
identification inside spleen granulomas, which were nu-
merous and almost replacing the spleen parenchyma.
She also showed intraabdominal lymphadenopathy and
elevated ferritin levels none of which are specific for
disseminated histoplasmosis but are highly suggestive
of this diagnosis in the appropriate patient [9]. Attempts
to culture H. capsulatum should always be pursued for a
definitive diagnosis; however it is a fastidious, slow-
growing organism. The disseminated form is hard to diag-
nose, especially in view of its difficulty to be isolated on
routine laboratory cultures and the negative serology that
often occurs in immunocompromised patients with dis-
seminated infection who often fail to manifest an immune
response [9]. Urine and serum antigens are usually used
to make a diagnosis; however, these antigens assays are
not always available. In our case, antigens were not access-
ible and the histopathologic diagnosis along with a strong
clinical suspicion and epidemiologic features provided ad-
equate information to diagnose and to start treatment.
Disseminated co-infection with these two agents is
rare but it has been previously described in patients
with HIV, making our case unique because our patient
was HIV negative [4]. The co-infection poses a chal-
lenge for diagnosis because the diseases share many
symptoms, such as fever, fatigue, night sweats, lymph-
adenopathy, cough, and dyspnea. Both diseases affect
the lungs, with cavitation and infiltration identifiable
through chest X-rays. They can both lead to pancyto-
penia, elevated liver enzymes and elevated acute phase
reactants like ferritin. If a biopsy of the affected organ
is available, then it is imperative to look for both fungal
and acid-fast organisms. Co-infection treatment also
represents a challenge because of the well-documented
interaction between rifampin and itraconazole [10].
Rifampin is an inductor of the Cytochrome P450 and re-
duces the serum concentrations of itraconazole. Rifabutin
is a common alternative to rifampin, but also decreases
the serum concentration of itraconazole, which is the drug
of choice for histoplasmosis [11]. Quinolones are effect-
ive against tuberculosis and its activity is also well
documented [12]. In clinical trials with renal transplant
patients, where rifampin decreases the drug levels of
immunotherapies, the use of quinolones as an alterna-
tive has shown favorable treatment outcomes [2]. The
daily dosing also blends into the tuberculosis regimen,
simplifying the treatment and helping increase patient
compliance.
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The observed clinical respiratory deterioration of our
patient was another challenge. It started shortly after
the initiation of TB treatment. Paradoxical tuberculosis
worsening syndrome, a form of IRIS, explains this
clinical deterioration. The discontinuation of TNF-α
therapy, 6 months before admission may also be an
important contributing factor. The patient’s initial im-
provement followed by rapid deterioration is consistent
with IRIS, the same as latter stabilization without alter-
ation of treatment regimen [13]. The recognition of this
paradoxical reaction was critical in our case to rule out
treatment failure, drug-resistance, or toxicity. IRIS is
commonly described after the initiation of highly active
antiretroviral therapy in HIV-patients; however it has
also been reported in non-HIV-patients following dis-
continuation of TNF-α therapy, corticosteroid with-
drawal, recovery of neutropenia after chemotherapy,
and disseminated TB treatment initiation [13, 14]. The
use of steroids and/or nonsteroidal anti-inflammatory
drugs (NSAIDs) and the optimal treatment duration in
TB-IRIS remains a controversial issue [13]. When ste-
roids are considered for the treatment of TB-IRIS, then
the usual course is 4–6 weeks. But in our case the de-
velopment of gastrointestinal bleeding while on mech-
anical ventilation led us to the early discontinuation of
steroids. The continuation of anti-tuberculosis treat-
ment without steroids or NSAIDs along with aggressive
supportive care led to improvement of our patient.
Conclusion
Opportunistic infections should be highly suspected in im-
munosuppressed patients on medications like TNF-α inhib-
itors or corticosteroids. Strict adherence to the tuberculosis
screening and treatment guidelines is recommended. Even
though the co-infection of histoplasmosis and tuberculosis
is rare, it should be suspected and assessed.
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